Skip to main content Accessibility help
×
Home

Predictors and Molecular Epidemiology of Community-Onset Extended-Spectrum β-Lactamase–Producing Escherichia coli Infection in a Midwestern Community

  • Ritu Banerjee (a1), Jacob Strahilevitz (a2), James R. Johnson (a3), Payai P. Nagwekar (a4), Donna M. Schora (a4), Ilene Shevrin (a5), Hongyan Du (a4), Lance R. Peterson (a4) and Ari Robicsek (a4)...

Abstract

Objective.

To identify predictors of community-onset extended-spectrum β-lactamase (ESBL)-producing Escherichia coli infection.

Design.

Prospective case-control study.

Setting.

Acute care hospitals and ambulatory clinics in the Chicago, Illinois, region.

Patients.

Adults with E. coli clinical isolates cultured in ambulatory settings or within 48 hours of hospital admission.

Methods.

Cases were patients with ESBL-producing E. coli clinical isolates cultured in ambulatory settings or within 48 hours of admission, and controls were patients with non-ESBL-producing E. coli isolates, matched to cases by specimen, location, and date. Clinical variables were ascertained through interviews and medical record review. Molecular methods were used to identify ESBL types, sequence type ST131, and aac(6′)-Ib-cr.

Results.

We enrolled 94 cases and 158 controls. Multivariate risk factors for ESBL-producing E. coli infection included travel to India in the past year (odds ratio [OR], 14.40 [95% confidence interval (CI), 2.92-70.95]), ciprofloxacin use (OR, 3.92 [95% CI, 1.90-8.1]), and age (OR, 1.04 [95% CI, 1.02-1.06]). Case isolates exhibited high prevalence of CTX-M-15 (78%), ST131 (50%), and aac(6′)-Ib-cr (66% of isolates with CTX-M-15).

Conclusions.

Providers should be aware of the increased risk of ESBL-producing E. coli infection among returned travelers, especially those from India.

Copyright

Corresponding author

Mayo Clinic, Division of Pediatric Infectious Diseases, 200 First Street SW, Rochester, MN 55905 (banerjee.ritu@mayo.edu)

References

Hide All
1.Marchaim, D, Gottesman, T, Schwartz, O, et al.National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2010;54:50995104.
2.DeKraker, M, Davey, P, Grundmann, H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med 2011;8:e1001104.
3.Tumbarello, M, Spanu, T, DiBidino, R, et al.Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010;54:40854091.
4.Hawkey, P, Jones, A. The changing epidemiology of resistance. J Antimicrob Chemother 2009;64:i3i10.
5.Peirano, G, Pitout, J. Molecular epidemiology of Escherichia coli producing CTX-M-beta lactamases: the worldwide emergence of clone ST131 025:H4. Int J Antimicrob Agents 2009;35:316321.
6.Rodriguez-Bano, J, Alcalá, J, Cisneros, J, et al.Escherichia coli producing SHV-type extended-spectrum beta lactamase is a significant cause of community-acquired infection. J Antimicrob Chemother 2009;63:781784.
7.Pitout, J, Nordmann, P, Laupland, K, Poirel, L. Emergence of Enterobacteriaceae producing extended-spectrum beta lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56:5259.
8.Doi, Y, Park, Y, Rivera, J, et al.Community-associated extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli infection in the United States. Clin Inject Dis 2013;56:641648.
9.Livermore, D, Canton, R, Gniadkowski, M, et al.CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59:165174.
10.Albrechtova, K, Dolejska, M, Cizek, A, et al.Dogs of nomadic pastoralists in northern Kenya are reservoirs of plasmid-medi-ated cephalosporin- and quinolone-resistant Escherichia coli, including pandemic clone B2-025-ST131. Antimicrob Agents Chemother 2012;56:40134017.
11.Geser, N, Stephan, R, Hachler, H. Occurrence and characteristics of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae in food producing animals, minced meat and raw milk. BMC Vet Res 2012;8:21.
12.Dolejska, M, Frolkova, P, Florek, M, et al.CTX-M-15 producing Escherichia coli clone B2-025b-ST131 and Klebsiella spp. isolates in municipal wastewater treatment plan efffluents. J Antimicrob Chemother 2011;66:27842790.
13.Deshpande, P, Vadwai, V, Shetty, A, Dalai, R, Soman, R, Rodrigues, C. No NDM-1 carriage in healthy persons from Mumbai: reassuring for now. J Antimicrob Chemother 2012;67:10461047.
14.Yang, H, Chen, H, Yang, Q, Chen, M, Want, H. High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6′)-Ib-a in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China. Antimicrob Agents Chemother 2008; 52:42684273.
15.Lautenbach, E, Patel, J, Bilker, W, Edelstein, P, Fishman, N. Extended spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:11621171.
16.Kang, C-I, Song, J-H, Chung, DR, et al. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents 2010;36:284287.
17.Ben-Ami, R, Rodriguez-Bano, J, Arslan, H, et al.A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682690.
18.Calbo, E, Romani, V, Xercavins, M, et al.Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006;57:780783.
19.Rodriquez-Bano, J, Alcalá, J, Cisneros, J, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008;168:18971902.
20.Colodner, R, Rock, W, Chazan, B, et al.Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163167.
21.Laupland, K, Church, D, Vidakovich, J, Mucenski, M, Pitout, J. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 2008;57:441448.
22.Johnson, J, Johnston, B, Clabots, C, Kuskowski, M, Castanheira, M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010;51:286294.
23.Nicolas-Chanoine, M-H, Blanco, J, Leflon-Guibout, V, et al.Intercontinental emergence of Escherichia coli clone 025:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008;61: 273281.
24.Cagnacci, S, Gualco, L, Debbia, E, Schito, G, Marchese, A. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups 025:H4-ST131 and 015:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol 2008;46:26052612.
25.Kang, C-I, Wi, YM, Lee, MY, et al.Epidemiology and risk factors of community-onset infections caused by extended spectrum beta lactamase producing Escherichia coli strains. J Clin Microbiol 2012;50:312317.
26.Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement (M100-S19). Wayne, PA: CLSI, 2009.
27.Xu, L, Ensor, V, Gossain, S, Nye, K, Hawkey, P. Rapid and simple detection of blaCTX.M genes by multiplex PCR assay. J Med Microbiol 2005;54:11831187.
28.Johnson, J, Menard, M, Johnston, B, Kuskowski, M, Nichol, K, Zhanel, G. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002-2004. Antimicrob Agents Chemother 2009;53:27332739.
29.Warburg, G, Korem, M, Robicsek, A, et al.Changes in aac(6′)-Ib-cr prevalence and fluoroquinolone resistance in nosocomial isolates of Escherichia coli collected from 1991-2005. Antimicrob Agents Chemother 2009;53:12681270.
30.Pregibon, D. Data analytic methods for matched case-control studies. Biometrics 1984;40:639651.
31.Hosmer, DW, Lemeshow, S. Applied Logistic Regression. New York: Wiley, 1989.
32.Freeman, JT, McBride, SJ, Heffernan, H, Bathgate, T, Pope, C, Ellis-Pegler, RB. Community-onset genitourinary tract infection due to CTX-M-15 producing Escherichia coli among travelers to the Indian subcontinent in New Zealand. Clin Infect Dis 2008;47: 689692.
33.Kennedy, K, Collignon, P. Colonisation with Escherichia coli resistant to “critically important” antibiotics: a high risk for international travellers. Eur J Clin Microbiol Infect Dis 2010;29: 15011506.
34.Weisenberg, S, Mediavilla, J, Chen, L, et al.Extended spectrum beta-lactamase producing Enterobacteriaceae in international travelers and non-travelers in New York City. PloS ONE 2012; 7:e45141.
35.Tande, D, Boirame-Gastrin, S, Munck, MR, et al.Intrafamilial transmission of extended-spectrum beta-lactamase-producing Escherichia coli and Salmonella enterica Babelsberg among the families of internationally adopted children. J Antimicrob Chemother 2010;65:859865.
36.Diwan, V, Chandran, S, Tamhankar, A, Lundborg, CS, Macaden, R. Identification of extended-spectrum beta-lactamase and quin-olone resistance genes in Escherichia coli isolated from hospital wastewater from central India. J Antimicrob Chemother 2012;67: 857859.
37.Rodrigues, C, Shukla, S, Jog, S, Mehta, A. Extended-spectrum beta-lactamase-producing flora in healthy persons. Emerg Infect Dis 2005;11:981982.
38.Tangden, T, Cars, O, Melhus, A, Lowdin, E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010;54:35643568.
39.Tham, J, Odenholt, I, Walder, M, Brolund, A, Ahl, J, Melander, E. Extended spectrum beta-lactamase-producing Escherichia coli in patients with travellers' diarrhoea. Scand J Infect Dis 2010;42: 275280.
40.Dhanji, H, Patel, R, Wall, R, et al.Variation in the genetic environments of blaCTX.M-15 in Escherichia colt from the faeces of travellers returning to the United Kingdom. J Antimicrob Chemother 2011;66:10051012.
41.Robicsek, A, Strahilevitz, J, Jacoby, GA, et al.Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006;12:8388.
42.Park, C, Robicsek, A, Jacoby, G, Sahm, D, Hooper, D. Prevalence in the United States of aac(6′)-Ib-cr encoding a ciprofloxacin modifying enzyme. Antimicrob Agents Chemother 2006;50:39533955.
43.Pitout, JDD, Campbell, L, Church, DL, Gregson, DB, Laupland, KB. Molecular characteristics of travel-related extended-spectrum beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region. Antimicrob Agents Chemother 2009;53: 25392543.
44.Kaye, KS, Harris, AD, Samore, M, Carmeli, Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005;26:346351.
45.Harris, A, Samore, M, Lipsitch, M, Kaye, K, Perencevich, E, Carmeli, Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin Infect Dis 2002;34:15581563.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed